BD Completes GeneOhm buy
This article was originally published in The Gray Sheet
Executive Summary
BD will launch a global initiative to reduce healthcare-associated infections after completing its acquisition of molecular diagnostic firm GeneOhm Sciences (1"The Gray Sheet" Jan. 16, 2006, p. 5). BD announced Jan. 10 that it would pay $230 mil., plus up to $25 mil. in milestone payments, to acquire the firm. Assays currently available from GeneOhm include the IDI-Strep B assay for detecting Group B Strep, and IDI-MRSA for detecting methicillin-resistant Staphylococcus aureus. BD has speculated that the market could be worth more than $500 mil...
You may also be interested in...
BD Targets Hospital-Associated Infections With $230 Mil. Acquisition
BD's acquisition of molecular diagnostic firm GeneOhm Sciences enters the medical technology company into the purportedly $500 mil.-plus healthcare-associated infections market
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.